- Home
- SKYE vs CXE Comparison
SKYE vs CXE Comparison
Compare SKYE & CXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- CXE
- Stock Information
- Founded
- SKYE 2012
- CXE 1989
- Country
- SKYE United States
- CXE United States
- Employees
- SKYE N/A
- CXE N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- CXE Investment Managers
- Sector
- SKYE Health Care
- CXE Finance
- Exchange
- SKYE Nasdaq
- CXE Nasdaq
- Market Cap
- SKYE 108.5M
- CXE 110.0M
- IPO Year
- SKYE N/A
- CXE N/A
- Fundamental
- Price
- SKYE $4.25
- CXE $3.72
- Analyst Decision
- SKYE Buy
- CXE
- Analyst Count
- SKYE 7
- CXE 0
- Target Price
- SKYE $15.50
- CXE N/A
- AVG Volume (30 Days)
- SKYE 294.2K
- CXE 62.9K
- Earning Date
- SKYE 11-06-2025
- CXE 01-01-0001
- Dividend Yield
- SKYE N/A
- CXE 4.36%
- EPS Growth
- SKYE N/A
- CXE N/A
- EPS
- SKYE N/A
- CXE 0.07
- Revenue
- SKYE N/A
- CXE N/A
- Revenue This Year
- SKYE N/A
- CXE N/A
- Revenue Next Year
- SKYE N/A
- CXE N/A
- P/E Ratio
- SKYE N/A
- CXE $51.00
- Revenue Growth
- SKYE N/A
- CXE N/A
- 52 Week Low
- SKYE $1.14
- CXE $2.95
- 52 Week High
- SKYE $6.51
- CXE $3.67
- Technical
- Relative Strength Index (RSI)
- SKYE 66.34
- CXE 75.86
- Support Level
- SKYE $3.96
- CXE $3.50
- Resistance Level
- SKYE $4.35
- CXE $3.58
- Average True Range (ATR)
- SKYE 0.28
- CXE 0.04
- MACD
- SKYE 0.09
- CXE 0.02
- Stochastic Oscillator
- SKYE 91.15
- CXE 97.50
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.